一分钟看懂
这是一项关于Viral Associated Malignancies的I 期研究，登记的药物或干预包括Pomalidomide；Nivolumab，当前状态为招募中。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pomalidomide；Nivolumab · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Institutes of Health Clinical Center · Bethesda
公开的入选条件
- * Histologically or cytologically proven selected virus-associated tumors that are systemic, metastatic or locally advanced and not amenable to curative treatment options or are relapsed/refractory to first-line therapy as appropriate for each tumor type as ou
- The following tumor types listed below are eligible, and require assessing of virus infection of the tumor cells with EBV EBER by in situ hybridization (ISH), KSHV LANA , p16, and Merkel cell polyomavirus large T antigen by immunohistochemistry (IHC) to docume
- --EBV-positive Hodgkin lymphoma meeting the following criteria:
- * Relapsed or refractory de novo classical Hodgkin lymphoma having failed standard first-line therapy; and
- * Unresponsive or progressive disease after treatment with brentuximab vedotin or may be brentuximab vedotin na(SqrRoot) ve but is ineligible or unable to receive brentuximab vedotin; and
- * Unresponsive or progressive disease after checkpoint inhibitor therapy;
- * Unresponsive or progressive disease after or is ineligible for autologous stem cell transplant (auto-SCT)
- --EBV-positive aggressive non-Hodgkin lymphomas meeting the following criteria:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04902443；登记信息更新于 2026-09-17。